EVMNNYSEPharmaceutical PreparationsFiscal year ends December 31
Evommune, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$5.27+0.10 (+1.93%)
Close on Oct 19, 2026
- Market cap
- $190.43M
- P/E (TTM)
- –
- Dividend yield
- –
Dividends
Evommune has not reported a dividend
No dividend per share appears in Evommune's annual filings since fiscal 2023.